These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12705166)

  • 21. Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.
    Napier JC; Francis R; Wright G
    BMJ; 2003 May; 326(7400):1212. PubMed ID: 12775633
    [No Abstract]   [Full Text] [Related]  

  • 22. A cost-utility analysis of interferon beta for multiple sclerosis.
    Parkin D; McNamee P; Jacoby A; Miller P; Thomas S; Bates D
    Health Technol Assess; 1998; 2(4):iii-54. PubMed ID: 9580870
    [No Abstract]   [Full Text] [Related]  

  • 23. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al].
    Labetouelle M
    J Fr Ophtalmol; 2001 Feb; 24(2):222. PubMed ID: 11332406
    [No Abstract]   [Full Text] [Related]  

  • 24. Interferon-beta therapy for MS: the dilemma of having choices.
    Khan O
    J Neurol Sci; 2004 Jul; 222(1-2):1. PubMed ID: 15240187
    [No Abstract]   [Full Text] [Related]  

  • 25. [Subacute cutaneous lupus erythematosus and interferon beta-1 a].
    Schmutz J; Barbaud A; Tréchot P
    Ann Dermatol Venereol; 2000 Feb; 127(2):237. PubMed ID: 10739993
    [No Abstract]   [Full Text] [Related]  

  • 26. Serono pays $44m to settle promotion of multiple sclerosis drug.
    Tanne JH
    BMJ; 2011 May; 342():d2922. PubMed ID: 21558361
    [No Abstract]   [Full Text] [Related]  

  • 27. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
    Schwid SR; Thorpe J; Sharief M; Sandberg-Wollheim M; Rammohan K; Wendt J; Panitch H; Goodin D; Li D; Chang P; Francis G; ;
    Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed drug eruption with interferon-beta-1b.
    Tai YJ; Tam M
    Australas J Dermatol; 2005 Aug; 46(3):154-7. PubMed ID: 16008645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction versus escalation therapy.
    Martinelli V; Comi G
    Neurol Sci; 2005 Dec; 26 Suppl 4():S193-9. PubMed ID: 16388357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythema elevatum et diutinum, multiple sclerosis and interferon beta.
    Gil M; Chizzolini C; Kaya G; Hauser C
    Dermatology; 2004; 209(1):75-6. PubMed ID: 15237277
    [No Abstract]   [Full Text] [Related]  

  • 34. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.
    Lugaresi A; Rottoli MR; Patti F
    Expert Rev Neurother; 2014 Sep; 14(9):1029-42. PubMed ID: 25109614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Funding of drug treatment of multiple sclerosis should not be delayed.
    Paty DW
    BMJ; 1997 Nov; 315(7116):1160-1. PubMed ID: 9374903
    [No Abstract]   [Full Text] [Related]  

  • 36. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Activation of psoriasis in patients undergoing treatment with interferon-beta].
    Navne JE; Hedegaard U; Bygum A
    Ugeskr Laeger; 2005 Aug; 167(32):2903-4. PubMed ID: 16109199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases.
    Ball NJ; Cowan BJ; Hashimoto SA
    J Cutan Pathol; 2009 Mar; 36(3):331-7. PubMed ID: 19032383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
    Hohlfeld R
    Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
    [No Abstract]   [Full Text] [Related]  

  • 40. Beta interferon and multiple sclerosis: why the fuss?
    Mumford CJ
    QJM; 1996 Jan; 89(1):1-3. PubMed ID: 8730337
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.